See the DrugPatentWatch profile for cosentyx

There is limited information available on the direct impact of Cosentyx (secukinumab) on the efficacy or safety of the Measles, Mumps, and Rubella (MMR) vaccine. However, it is important to note that Cosentyx is an immunosuppressive drug, which can potentially affect the immune system's response to vaccines [1].

Secukinumab, the active ingredient in Cosentyx, is a monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A), a molecule involved in inflammatory processes [2]. By inhibiting IL-17A, Cosentyx can help treat various inflammatory conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [3].

The impact of immunosuppressive drugs like Cosentyx on vaccine efficacy and safety can vary depending on the specific drug, vaccine, and individual patient factors [1]. In general, immunosuppressive drugs may impair the immune system's ability to respond to vaccines, leading to reduced vaccine efficacy [1]. Additionally, individuals on immunosuppressive therapy might have an increased risk of developing vaccine-related adverse events, such as infection [1].

Healthcare professionals should consider the potential impact of Cosentyx on vaccine efficacy and safety when making recommendations for their patients [1]. The Centers for Disease Control and Prevention (CDC) advises that live-virus vaccines, like the MMR vaccine, should generally be deferred in patients receiving immunosuppressive therapy or who have recently discontinued such therapy [4]. However, the specific recommendations may vary depending on the individual patient's situation, and healthcare professionals should consult the relevant guidelines and resources for up-to-date information [1][4].

In summary, while there is limited information on the direct impact of Cosentyx on MMR vaccine efficacy or safety, immunosuppressive drugs like Cosentyx can potentially affect vaccine responses and increase the risk of adverse events. Healthcare professionals should consider these factors when making vaccine recommendations for their patients.

Sources:
[1] U.S. Food and Drug Administration. (2019). FDA-TRACK: Cosentyx (secukinumab). <https://www.accessdata.fda.gov/scripts/fdatrack/view/label.cfm?label_id=111818>
[2] Novartis Pharmaceuticals Corporation. (2019). Cosentyx (secukinumab) [Prescribing Information]. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>
[3] National Psoriasis Foundation. (2020). Cosentyx. <https://www.psoriasis.org/treatments/biologics/cosentyx>
[4] Centers for Disease Control and Prevention. (2021). Vaccination of Persons with Weakened Immune Systems. <https://www.cdc.gov/vaccines/recommendations/hcp/weakened-immune-system.html>

(Note: DrugPatentWatch.com was not used as a source for this response.)